Attenuation of diabetic nephropathy by tocotrienol: Involvement of NFkB signaling pathway

Life Sciences

Volumn 84, Issue 9-10, 2009, Pages 296-301

  Kuhad, Anurag ^a   Chopra, Kanwaljit ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apoptosis; Caspase 3; Diabetic nephropathy; NF ; Oxidative nitrosative stress; TGF 1; TNF ; Tocotrienol

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; CASPASE 3; CATALASE; CREATININE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; NITRIC OXIDE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOPLASM; DIABETIC NEPHROPATHY; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; KIDNEY FUNCTION; LIPID PEROXIDATION; MALE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINE VOLUME;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; HUMANS; MALE; NF-KAPPA B; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TOCOTRIENOLS;

RATTUS;

EID: 59649104131     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.12.014     Document Type: Article

References (55)

1. Ahn K.S., Sethi G., Krishnan K., and Aggarwal B.B. Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. Journal of Biological Chemistry 282 (2007) 809-820
2. Allen D.A., Harwood S., Varagunam M., Raftery M.J., and Yaqoob M.M. High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. Journal of the Federation of American Societies for Experimental Biology 17 (2003) 908-910
3. Begum A.N., and Terao J. Protective effect of alpha-tocotrienol against free radical-induced impairment of erythrocyte deformability. Bioscience Biotechnology and Biochemistry 66 (2002) 398-403
4. Bohle A., Wehrmann M., Bogenschutz O., Batz C., Muller C.A., and Muller G.A. The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis. Pathology Research and Practice 187 (1991) 251-259
5. Cheng H.F., Wang C.J., Moeckel G.W., Zhang M.Z., McKanna J.A., and Harris R.C. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney International 62 (2002) 929-939
6. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., and Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney International 69 (2006) 73-80
7. Claiborne A. In: Greenwald R.A. (Ed). CRC Handbook of methods for oxygen radical research (1985), CRC Press, Boca Raton, Fla 283-284
8. Craven P.A., Melhem M.F., and DeRubertis F.R. Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney International 42 (1992) 937-946
9. DiPetrillo K., and Gesek F.A. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. American Journal of Nephrology 24 (2004) 352-359
10. Dipetrillo K., Coutermarsh B., and Gesek F.A. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. American Journal of Physiology Renal Physiology 284 (2003) F113-F121
11. Flyvbjerg A., Khatir D.S., Jensen L.J., Dagnaes-Hansen F., Gronbaek H., and Rasch R. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Current Pharmaceutical Design 10 (2004) 3385-3394
12. Galkina E., and Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. Journal of American Society of Nephrology 17 (2006) 368-377
13. Gilbert R.E., and Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. Kidney International 56 (1999) 1627-1637
14. Hostetter T.H. Hypertrophy and hyperfunction of the diabetic kidney. Journal of Clinical Investigation 107 (2001) 161-162
15. Jollow D.J., Mitchell J.R., Zampaglione N., and Gillette J.R. Bromobenze induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzenoxide as the hepatotoxic intermediate. Pharmacology 11 (1974) 151-169
16. Karin M., and Greten F.R. NF-kappaB linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology 5 (2005) 749-759
17. Komers R., Schutzer W., Xue H., Oyama T.T., Lindsley J.N., and Anderson S. Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats. Translational Research 150 (2007) 343-349
18. Kono Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Archives of Biochemistry and Biophysics 186 (1978) 189-195
19. Konrad R.J., Mikolaenko I., Tolar J.F., Liu K., and Kudlow J.E. The potential mechanism of the diabetogenic action of streptozotocin: inhibition of pancreatic beta-cell O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase. Biochemical Journal 356 (2001) 31-41
20. Kuhad A., and Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. European Journal of Pharmacology 576 (2007) 34-42
21. Kuhad A., Sharma S., and Chopra K. Lycopene attenuates thermal hyperalgesia in a diabetic mouse model of Neuropathic pain. European Journal of Pain 12 5 (2008) 624-632
22. Levine D.Z. Hyperfiltration, nitric oxide, and diabetic nephropathy. Current Hypertension Reports 8 (2006) 153-157
23. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nature Reviews Immunology 2 (2002) 725-734
24. Mezzano S., Droguett A., Burgos M.E., Ardiles L., Flores C., Schneider H., Ruiz-Ortega M., and Egido J. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrology Dialysis and Transplant 19 (2004) 2505-2512
25. Mora C., and Navarro J.F. Inflammation and diabetic nephropathy. Current Diabetes Reports 6 (2006) 463-468
26. Nakagawa T. Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease. American Journal of Physiology Renal Physiology 292 (2007) F1665-F1672
27. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., and Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42 (1993) 450-456
28. Navarro J.F., and Mora C. Role of inflammation in diabetic complications. Nephrology Dialysis and Transplant 20 (2005) 2601-2604
29. Navarro J., Milena F., Mora C., Leon C., Claverie F., Flores C., and Garcia J. Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin converting enzyme inhibition. Kidney International Supplement 99 (2005) S98-S102
30. Navarro J.F., Milena F.J., Mora C., Leon C., and Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. American Journal of Nephrology 26 (2006) 562-570
31. Navarro-Gonzalez J.F., and Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. Journal of American Society of Nephrology 19 (2008) 433-442
32. O'Connor A.S., and Schelling J.R. Diabetes and the kidney. American Journal of Kidney Disease 46 (2005) 766-773
33. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 95 (1979) 351-358
34. Osakada F., Hashino A., Kume T., Katsuki H., Kaneko S., and Akaike A. Alpha-tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. Neuropharmacology 47 (2004) 904-915
35. Pantsulaia T. Role of TGF-beta in pathogenesis of diabetic nephropathy. Georgian Medical News 131 (2006) 13-18
36. Petersen M., Thorikay M., Deckers M., van Dinther M., Grygielko E.T., Gellibert F., de Gouville A.C., Huet S., ten Dijke P., and Laping N.J. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney International 73 (2008) 705-715
37. Quaggin S.E., and Coffman T.M. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link?. Journal of American Society of Nephrology 18 (2007) 364-366
38. Sakai N., Wada T., Furuichi K., Iwata Y., Yoshimoto K., Kitagawa K., Kokubo S., Kobayashi M., Hara A., Yamahana J., Okumura T., Takasawa K., Takeda S., Yoshimura M., Kida H., and Yokoyama H. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. American Journal of Kidney Disease 45 (2005) 54-65
39. Schena F.P., and Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. Journal of American Society of Nephrology 16 (2005) S30-S33
40. Schmid H., Boucherot A., Yasuda Y., Henger A., Brunner B., Eichinger F., Nitsche A., Kiss E., Bleich M., Grone H.J., Nelson P.J., Schlondorff D., Cohen C.D., Kretzler M., and for European Renal cDNA Bank (ERCB) Consortium. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55 (2006) 2993-3003
41. Schreiner G.F., and Kohan D.E. Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes. American Journal of Physiology 258 (1990) F761-F767
42. Sen C.K., Khanna S., and Roy S. Tocotrienols in health and disease: the other half of the natural vitamin E family. Molecular Aspects of Medicine 28 (2007) 692-728
43. Serbinova E., Kagan V., Han D., and Packer L. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radical. Biology and Medicine 10 (1991) 263-275
44. Serbinova E.A., and Packer L. Antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Methods in Enzymology 234 (1994) 354-366
45. Sharma S., Anjaneyulu M., Kulkarni S.K., and Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 76 (2006) 69-75
46. Sharma S., Kulkarni S.K., and Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clinical Experimental Pharmacology and Physiology 33 (2006) 940-945
47. Sugimoto H., Shikata K., Wada J., Horiuchi S., and Makino H. Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible oxide synthase in diabetic rat glomerli. Diabetologia 42 (1999) 878-886
48. Sugimoto K., Tsuruoko S., and Fujimura A. Effect of enalapril on diabetic nephropathy in OLETF rats: the role of an anti-oxidative action in its protective properties. Clinical Experimental Pharmacology Physiology 28 (2001) 829-830
49. Suzuki Y.J., Tsuchiya M., Wassall S.R., Choo Y.M., Govil G., Kagan V.E., and Packer L. Structural and dynamic membrane properties of alpha-tocopherol and alpha-tocotrienol: implication to the molecular mechanism of their antioxidant potency. Biochemistry 32 (1993) 10692-10699
50. Tuttle K.R. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. Journal of American Society of Nephrology 16 (2005) 1537-1538
51. Weber S.U., Thiele J.J., Han N., Luu C., Valacchi G., Weber S., and Packer L. Topical alpha-tocotrienol supplementation inhibits lipid peroxidation but fails to mitigate increased transepidermal water loss after benzoyl peroxide treatment of human skin. Free Radical Biology & Medicine 34 (2003) 170-176
52. Williams M.D., and Nadler J.L. Inflammatory mechanisms of diabetic complications. Current Diabetes Reports 7 (2007) 242-248
53. Williams M.E., and Tuttle K.R. The next generation of diabetic nephropathy therapies: an update. Advance Chronic Kidney Disease 12 (2005) 212-222
54. Yamamoto Y., and Gaynor R.B. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Current Molecular Medicine 1 (2001) 287-296
55. Zeisberg M., Strutz F., and Müller G.A. Role of fibroblast activation in inducing interstitial fibrosis. Journal of Nephrology 13 (2000) S111-S120